- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03244267
App Reminder on ASA Adherence
Impact of a Smartphone App Reminder on Adherence Aspirin Prescribed as Anti-Thrombotic Therapy
The purpose of this study is to explore the impact of using a smartphone app reminder on medication adherence twice daily in adults prescribed 81 milligrams of aspirin for 35 days as anti-thrombotic therapy after knee or hip arthroplasty.
This study will randomly assign participants to get usual postoperative care which is teaching with verbal instructions and printed information about taking the aspirin at the time of discharge, or to have an app on your smartphone with preset reminders in addition to usual postoperative discharge teaching after surgery.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The purpose of this study is to evaluate the impact of using a smartphone application (app) reminder on medication adherence twice daily in 200 adults prescribed 81 milligrams of aspirin (ASA) for 35 days as anti-thrombotic therapy after knee or hip arthroplasty. The aim is to determine if an app downloaded on a smartphone that reminds patients twice a day to take their ASA as prescribed will improve ASA adherence and clinical outcomes for patients after total knee and total hip joint arthroplasty compared to those in the usual care.
This is a two group, randomized control study with random assignment into the control group for usual care or the intervention group to receive a medication reminder app for their smart phone (daily for 35 days) plus usual care. Participants will receive a baseline interview for demographic and other data and 36 day follow-up assessment, both conducted in person.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30084
- Emory Orthopedic and Spine Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Prescribed aspirin 81 mg twice a day for 35 days
- Ability to write and speak English
- Have a smart phone with the capacity to download and set an app
- Own and use a smart phone for communication purposes
Exclusion Criteria:
- Diagnosis of mental illness
- Do not own a smart phone
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur actif: Standard Education
Participants randomized to this arm will receive the standard education provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery.
|
Participants will receive the usual verbal education and printed information provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery, medication dosage and scheduling.
|
Expérimental: Medication Reminder App + Standard Education
Participants randomized to this arm will use a smartphone app with preset reminders to take aspirin to prevent thromboembolic events after orthopedic surgery in addition to usual postoperative discharge teaching.
|
Participants will receive the usual verbal education and printed information provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery, medication dosage and scheduling.
Participants will use a medication reminder app that is set in collaboration with the participants for times that fit into their daily lifestyle.
The app will alert participants when it is time (selected by the participant) to take their medication.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Proportion of Pills Taken
Délai: Post- Operative Visit (Day 36)
|
The proportion of pills taken is defined as the percentage of pills taken by study participants.
|
Post- Operative Visit (Day 36)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
AIDS Clinical Trials Group (ACTG) Adherence Questionnaire Score
Délai: Post- Operative Visit (Day 36)
|
The ACTG Adherence Questionnaire consists of 19 items measuring different aspects of efficacy (or confidence) in the management of one's medication.
Each item is rated from 0 ("I cannot do at all") to 10 ("Sure I can do"), with total scores found by summing responses to individual items and dividing by 19.
Higher scores correspond to higher levels of medication self-efficacy.
|
Post- Operative Visit (Day 36)
|
Aspirin (ASA) Self-Efficacy Scale Score
Délai: Post- Operative Visit (Day 36)
|
The ASA Self-Efficacy Scale consists of 19 items measuring different aspects of efficacy (or confidence) in the management of one's medication.
Each item is rated from 0 ("I cannot do at all") to 10 ("Sure I can do"), with total scores found by summing responses to individual items and dividing by 19.
Higher scores correspond to higher levels of medication self-efficacy.
|
Post- Operative Visit (Day 36)
|
Number of Thromboembolic Events
Délai: Post- Operative Visit (Day 36)
|
Clinical outcomes will be assessed at follow-up by self-report questions to ascertain if any thromboembolic events occurred.
|
Post- Operative Visit (Day 36)
|
Aspirin (ASA) General Adherence Scale Score
Délai: Post- Operative Visit (Day 36)
|
The ASA General Adherence Scale measures the ease and ability to adhere to the ASA regimen as prescribed.
It is scored by summing responses to the individual items and creating a total score.
Higher scores indicate better self-reported adherence.
|
Post- Operative Visit (Day 36)
|
Unified Theory of Acceptance and Use of Technology (UTAUT2) Survey Score
Délai: Baseline (Pre-Intervention)
|
The UTAUT2 measures antecedents (performance expectancy, effort expectancy, hedonic motivation) and behavioral intent to use mobile apps.
Items are scored using a 7-point Likert scale, from 1 (strongly disagree) to 7 (strongly agree).
Survey totals range between 14 and 112.
Higher scores are indicative of greater acceptance and intent to adopt the target technology.
|
Baseline (Pre-Intervention)
|
Performance Expectancy Subscale Score
Délai: Baseline (Pre-Intervention)
|
The Performance Expectancy Subscale measures the perceived benefits of mobile app technology to the consumer.
Scores range from 4 to 28, with higher totals indicating better perceptions of technology-related benefits.
|
Baseline (Pre-Intervention)
|
Effort Expectancy Subscale Score
Délai: Baseline (Pre-Intervention)
|
The Effort Expectancy Subscale measures the ease with which the consumer can learn and operate an app.
Scores range from 4 to 28, with higher totals indicating greater beliefs that the technology is easy and accessible.
|
Baseline (Pre-Intervention)
|
Hedonic Motivation Subscale Score
Délai: Baseline (Pre-Intervention)
|
The Hedonic Motivation subscale measures the enjoyment, the consumer experiences from using an app.
Respondents answer each item on a 7-point Likert-type scale ranging from 1 (Absolutely True) to 7 (Absolutely Untrue).
Scoring is kept continuous with higher scores indicating greater enjoyment.
|
Baseline (Pre-Intervention)
|
Behavioral Intent Subscale Score
Délai: Baseline (Pre-Intervention)
|
The Behavioral Intent Subscale measures the decision to use a mobile app.
Scores range from 3 to 21, with higher totals indicating a greater intent to use or adopt an app.
|
Baseline (Pre-Intervention)
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Deborah Wittig-Wells, PhD, Emory University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IRB00094970
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Standard Education
-
Universidad San SebastiánUniversidad de Valparaiso; Fondo de Fomento al Desarrollo Científico y Tecnológico...RecrutementGain de poids gestationnel | Obésité maternelleChili
-
Oregon Research InstituteComplétéTrouble lié à l'utilisation de substances | DélinquanceÉtats-Unis
-
University of PennsylvaniaRestaurant AssociatesActif, ne recrute pasObésité | Gain de poids | Préférences alimentaires | Sélection de nourritureÉtats-Unis
-
University of MichiganInscription sur invitationLa dépression | Anxiété | Trouble du sommeil | DépendanceÉtats-Unis
-
Institute of Cardiology, Warsaw, PolandInconnueRéadaptation cardiaquePologne
-
Lievensberg ZiekenhuisInconnueObésité morbide | Pontage gastrique | Chirurgie bariatriquePays-Bas
-
Shanghai Zhongshan HospitalInconnueTumeurs | Lymphome | Inflammation | Cancer | Infection | Sarcoïde | Lésion de masseChine
-
Jiangsu HengRui Medicine Co., Ltd.Actif, ne recrute pasAnémie aplasique sévèreChine
-
Swiss Group for Clinical Cancer ResearchRésiliéCancer colorectal métastatiqueSuisse, L'Autriche
-
University Hospital, BordeauxInstitut National de la Santé Et de la Recherche Médicale, France; Université... et autres collaborateursComplétéLa maladie d'AlzheimerFrance